- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Not listed
- Lead sponsor
- Natalie Torok
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 575
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Atorvastatin, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Durham, North Carolina
- Conditions
- Non Alcoholic Steatohepatitis
- Interventions
- Saroglitazar Magnesium 2mg, Saroglitazar Magnesium 4mg, Placebos
- Drug
- Lead sponsor
- Zydus Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Jackson, Mississippi • Germantown, Tennessee • Hermitage, Tennessee + 2 more
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- LJN452
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Knoxville, Tennessee
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- GSK4532990
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Chula Vista, California • Montclair, California • San Diego, California + 8 more
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
- Interventions
- Metabolic surgery, Incretin-Based Therapy
- Procedure · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Miricorilant, Fluvoxamine
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- EDP-305, Oral Contraceptive
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Spironolactone 100mg, Placebo oral capsule
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 130
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more
- Conditions
- Food Insecurity
- Interventions
- Food Security Screening & Referral Program
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Diego, California
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL, Semaglutide placebo, NNC0174 0833 10 mg/mL, NNC0174 0833 placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 70
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 59 more
- Conditions
- Nonalcoholic Fatty Liver
- Interventions
- PXL770, Placebo
- Drug
- Lead sponsor
- Poxel SA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Empagliflozin 10 MG, Placebo Oral Tablet
- Drug
- Lead sponsor
- Justin Ryder
- Other
- Eligibility
- 16 Years to 20 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
- Interventions
- BT-NCBT-00X
- Device
- Lead sponsor
- Better Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Peoria, Arizona
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- LFSD
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Years to 9 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Fish Oil Supplementation, Placebo Supplementation
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Liver Multi Scan
- Diagnostic Test
- Lead sponsor
- Perspectum
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- Chandler, Arizona • Chicago, Illinois • Indianapolis, Indiana + 4 more
- Conditions
- Gestational Diabetes Mellitus in Pregnancy
- Interventions
- Subjects with Gestational Diabetes, Controls without Gestational Diabetes
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
- Interventions
- AZD4831, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 13 more
- Conditions
- Positron Emission Tomography
- Interventions
- 18F-DPA-714, 18F-FDG
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
- Interventions
- Fibroscan of Liver, Low-dose non-contrast CT
- Device · Procedure
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York